JP2023537943A5 - - Google Patents
Info
- Publication number
- JP2023537943A5 JP2023537943A5 JP2023509499A JP2023509499A JP2023537943A5 JP 2023537943 A5 JP2023537943 A5 JP 2023537943A5 JP 2023509499 A JP2023509499 A JP 2023509499A JP 2023509499 A JP2023509499 A JP 2023509499A JP 2023537943 A5 JP2023537943 A5 JP 2023537943A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- rnai construct
- sense strand
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025282055A JP2026049002A (ja) | 2020-08-13 | 2025-12-25 | MARC1発現を阻害するためのRNAiコンストラクト及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065190P | 2020-08-13 | 2020-08-13 | |
| US63/065,190 | 2020-08-13 | ||
| US202163214016P | 2021-06-23 | 2021-06-23 | |
| US63/214,016 | 2021-06-23 | ||
| PCT/US2021/045784 WO2022036126A2 (en) | 2020-08-13 | 2021-08-12 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282055A Division JP2026049002A (ja) | 2020-08-13 | 2025-12-25 | MARC1発現を阻害するためのRNAiコンストラクト及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537943A JP2023537943A (ja) | 2023-09-06 |
| JP2023537943A5 true JP2023537943A5 (cg-RX-API-DMAC7.html) | 2024-08-21 |
| JP7880324B2 JP7880324B2 (ja) | 2026-06-25 |
Family
ID=77640774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509499A Active JP7880324B2 (ja) | 2020-08-13 | 2021-08-12 | MARC1発現を阻害するためのRNAiコンストラクト及び方法 |
| JP2025282055A Pending JP2026049002A (ja) | 2020-08-13 | 2025-12-25 | MARC1発現を阻害するためのRNAiコンストラクト及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282055A Pending JP2026049002A (ja) | 2020-08-13 | 2025-12-25 | MARC1発現を阻害するためのRNAiコンストラクト及び方法 |
Country Status (17)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220264823A1 (en) * | 2021-02-24 | 2022-08-25 | Syngenta Crop Protection Ag | Soybean variety |
| US20220338438A1 (en) * | 2021-04-21 | 2022-10-27 | Syngenta Crop Protection Ag | A soybean variety |
| US11655473B2 (en) * | 2021-05-28 | 2023-05-23 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression |
| CA3225054A1 (en) * | 2021-07-08 | 2023-02-12 | Sun Woo Hong | Rnai agent targeting marc1 gene, and use thereof |
| US20230240241A1 (en) * | 2022-01-28 | 2023-08-03 | Pioneer Hi-Bred International, Inc. | Soybean variety 5pryl83 |
| US20230240232A1 (en) * | 2022-01-28 | 2023-08-03 | Pioneer Hi-Bred International, Inc. | Soybean variety 5psym14 |
| US12635649B2 (en) * | 2022-02-16 | 2026-05-26 | Syngenta Crop Protection Ag | Soybean line EC2020472 |
| KR20250043473A (ko) * | 2022-07-27 | 2025-03-28 | 이-테라퓨틱스 피엘씨 | 핵산 화합물 |
| US20240268301A1 (en) * | 2023-02-10 | 2024-08-15 | Pioneer Hi-Bred International, Inc. | Soybean variety 5ptcn76 |
| WO2024186171A1 (ko) * | 2023-03-08 | 2024-09-12 | 올릭스 주식회사 | 비만의 예방 또는 치료용 RNAi 제제 및 이를 이용한 병용 요법 |
| EP4680249A1 (en) * | 2023-03-16 | 2026-01-21 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), pharmaceutical compositions thereof, and methods of use |
| CN118853663A (zh) * | 2023-04-28 | 2024-10-29 | 北京福元医药股份有限公司 | 用于抑制marc1基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
| US12690546B1 (en) * | 2024-02-28 | 2026-07-28 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PQRB49 |
| US20250268198A1 (en) * | 2024-02-28 | 2025-08-28 | Pioneer Hi-Bred International, Inc. | Soybean variety 5pgbu05 |
| US12653137B2 (en) * | 2024-02-28 | 2026-06-16 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PPZM06 |
| US12702109B1 (en) * | 2024-02-28 | 2026-08-11 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PDKJ08 |
| US12690549B2 (en) * | 2024-02-28 | 2026-07-28 | Pioneer Hi-Bred International, Inc. | Soybean line 5PHSB14 |
| US12677793B2 (en) * | 2024-02-28 | 2026-07-14 | Pioneer Hi-Bred International, Inc. | Soybean line 5PAKS02 |
| US12702108B1 (en) * | 2024-02-28 | 2026-08-11 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PVEA23 |
| US12685285B2 (en) * | 2024-02-28 | 2026-07-21 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PYSG46 |
| US12653134B2 (en) * | 2024-02-28 | 2026-06-16 | Pioneer Hi-Bred International, Inc. | Soybean variety 5PEVE11 |
| US12690547B1 (en) * | 2024-02-28 | 2026-07-28 | Pioneer Hi-Bred International, Inc. | Soybean line 5PDBH03 |
| US12696865B1 (en) * | 2024-02-28 | 2026-08-04 | Pioneer Hi-Bred International, Inc. | Soybean line 5PLYF71 |
| CN121759452A (zh) * | 2024-09-30 | 2026-03-31 | 北京福元医药股份有限公司 | 用于抑制MARC1基因表达的siRNA及其缀合物和用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| JP4335310B2 (ja) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用 |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) * | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US20110081362A1 (en) * | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| US10835581B2 (en) | 2017-11-28 | 2020-11-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method of treating insulin resistance |
| EP4541352A3 (en) * | 2018-07-06 | 2025-07-16 | Algernon Pharmaceuticals Inc. | Compositions and methods for treating non-alcoholic steatohepatitis |
| SG11202105900UA (en) | 2018-12-10 | 2021-07-29 | Amgen Inc | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| CN110468196B (zh) * | 2019-08-20 | 2020-04-28 | 南京市第一医院 | 一种预测氯吡格雷抵抗的生物标志物的应用及其试剂盒 |
| WO2021237097A1 (en) * | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
-
2021
- 2021-08-12 EP EP21766066.1A patent/EP4196584A2/en active Pending
- 2021-08-12 PE PE2023000271A patent/PE20230993A1/es unknown
- 2021-08-12 CR CR20230126A patent/CR20230126A/es unknown
- 2021-08-12 CA CA3190868A patent/CA3190868A1/en active Pending
- 2021-08-12 IL IL300360A patent/IL300360A/en unknown
- 2021-08-12 CN CN202180055964.4A patent/CN116194119A/zh active Pending
- 2021-08-12 US US17/401,114 patent/US20220047621A1/en active Pending
- 2021-08-12 KR KR1020237008366A patent/KR20230046319A/ko active Pending
- 2021-08-12 WO PCT/US2021/045784 patent/WO2022036126A2/en not_active Ceased
- 2021-08-12 AU AU2021326521A patent/AU2021326521A1/en active Pending
- 2021-08-12 MX MX2023001786A patent/MX2023001786A/es unknown
- 2021-08-12 JP JP2023509499A patent/JP7880324B2/ja active Active
- 2021-08-13 TW TW110129910A patent/TW202221124A/zh unknown
- 2021-08-13 UY UY0001039382A patent/UY39382A/es not_active Application Discontinuation
-
2023
- 2023-02-09 CL CL2023000407A patent/CL2023000407A1/es unknown
- 2023-02-12 JO JOJO/P/2023/0030A patent/JOP20230030A1/ar unknown
- 2023-03-10 CO CONC2023/0002966A patent/CO2023002966A2/es unknown
-
2025
- 2025-12-25 JP JP2025282055A patent/JP2026049002A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| TWI880645B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP2023504744A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518125A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524151A5 (cg-RX-API-DMAC7.html) | ||
| US20160289677A1 (en) | APOB Antisense Conjugate Compounds | |
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| IL300360A (en) | RNAi constructs and methods to inhibit MARC1 expression | |
| RU2015154721A (ru) | КОМПОЗИЦИИ НА ОСНОВЕ RNAi SERPINA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| IL310929A (en) | Preparations and methods for inhibiting expression of angiopoietin-like protein 3 | |
| JP2024538859A5 (cg-RX-API-DMAC7.html) | ||
| GB2629679A (en) | Dual silencing | |
| CN117070517A (zh) | 用于抑制血管紧张素原表达的siRNA、其缀合物和药物组合物及用途 | |
| WO2022089486A1 (zh) | 抑制PCSK9基因表达的siRNA及其修饰物与应用 | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| JP2022534402A5 (cg-RX-API-DMAC7.html) | ||
| WO2023284559A1 (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| WO2023208109A9 (zh) | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 | |
| JP2024528701A5 (cg-RX-API-DMAC7.html) | ||
| KR20260040626A (ko) | 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도 | |
| CN119343449A (zh) | 用于抑制angptl3表达的rnai剂及其应用 | |
| JP2025512771A5 (cg-RX-API-DMAC7.html) | ||
| JP2025517965A5 (cg-RX-API-DMAC7.html) | ||
| RU2822093C1 (ru) | Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке | |
| RU2024107655A (ru) | Композиции и способы ингибирования экспрессии ангиопоэтин-подобного белка 3 (angptl3) |